{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T21:03:25Z","timestamp":1789506205992,"version":"build-2803163510"},"reference-count":230,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Funct Integr Genomics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10142-025-01563-8","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T06:53:23Z","timestamp":1741244003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Polycomb repressive complex 2 (PRC2) pathway\u2019s role in cancer cell plasticity and drug resistance"],"prefix":"10.1007","volume":"25","author":[{"given":"Pouya","family":"Goleij","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Mahdi","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Amin Khazeei","family":"Tabari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahboube","family":"Hadipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aryan","family":"Rezaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Javan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pantea Majma","family":"Sanaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana\u00e9 S.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Daglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haroon","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"1563_CR1","doi-asserted-by":"crossref","first-page":"5582","DOI":"10.1158\/0008-5472.CAN-05-3575","volume":"66","author":"PH Abbosh","year":"2006","unstructured":"Abbosh PH, Montgomery JS, Starkey JA, Novotny M, Zuhowski EG, Egorin MJ, Moseman AP, Golas A, Brannon KM, Balch C (2006) Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Can Res 66:5582\u20135591","journal-title":"Can Res"},{"key":"1563_CR2","doi-asserted-by":"crossref","unstructured":"Abu el Maaty MA, Terzic J, Keime C, Rovito D, Lutzing R, Yanushko D, Parisotto M, Grelet E, Namer IJ, Lindner V (2022) Hypoxia-mediated stabilization of HIF1A in prostatic intraepithelial neoplasia promotes cell plasticity and malignant progression. Sci Adv 8:eabo2295","DOI":"10.1126\/sciadv.abo2295"},{"key":"1563_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-018-0536-6","volume":"10","author":"E Ahl\u00e9n Bergman","year":"2018","unstructured":"Ahl\u00e9n Bergman E, Hartana CA, Johansson M, Linton LB, Berglund S, Hyllienmark M, Lundgren C, Holmstr\u00f6m B, Palmqvist K, Hansson J (2018) Increased CD4+ T cell lineage commitment determined by CpG methylation correlates with better prognosis in urinary bladder cancer patients. Clin Epigenetics 10:1\u201315","journal-title":"Clin Epigenetics"},{"key":"1563_CR4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/jnc.14152","volume":"143","author":"F Ahmad","year":"2017","unstructured":"Ahmad F, Patrick S, Sheikh T, Sharma V, Pathak P, Malgulwar PB, Kumar A, Joshi SD, Sarkar C, Sen E (2017) Telomerase reverse transcriptase (TERT)-enhancer of zeste homolog 2 (EZH2) network regulates lipid metabolism and DNA damage responses in glioblastoma. J Neurochem 143:671\u2013683","journal-title":"J Neurochem"},{"key":"1563_CR5","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1242\/dev.091553","volume":"140","author":"L Aloia","year":"2013","unstructured":"Aloia L, Di Stefano B, Di Croce L (2013) Polycomb complexes in stem cells and embryonic development. Development 140:2525\u20132534","journal-title":"Development"},{"key":"1563_CR6","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.4161\/cc.25163","volume":"12","author":"M Amatangelo","year":"2013","unstructured":"Amatangelo M, Garipov A, Li H, Conejo-Garcia JR, Speicher D, Zhang R (2013) Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell Cycle 12:2113\u20132119","journal-title":"Cell Cycle"},{"key":"1563_CR7","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41417-022-00555-1","volume":"30","author":"R An","year":"2023","unstructured":"An R, Li Y-Q, Lin Y-L, Xu F, Li M-M, Liu Z (2023) EZH1\/2 as targets for cancer therapy. Cancer Gene Ther 30:221\u2013235","journal-title":"Cancer Gene Ther"},{"key":"1563_CR8","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1500737","volume":"1","author":"S Aranda","year":"2015","unstructured":"Aranda S, Mas G, Di Croce L (2015) Regulation of gene transcription by polycomb proteins. Sci Adv 1:e1500737","journal-title":"Sci Adv"},{"key":"1563_CR9","doi-asserted-by":"publisher","first-page":"3094","DOI":"10.1084\/jem.20180570","volume":"215","author":"IM Ari\u00ebs","year":"2018","unstructured":"Ari\u00ebs IM, Bodaar K, Karim SA, Chonghaile TN, Hinze L, Burns MA, Pfirrmann M, Degar J, Landrigan JT, Balbach S, Peirs S, Menten B, Isenhart R, Stevenson KE, Neuberg DS, Devidas M, Loh ML, Hunger SP, Teachey DT, Rabin KR, Winter SS, Dunsmore KP, Wood BL, Silverman LB, Sallan SE, Van Vlierberghe P, Orkin SH, Knoechel B, Letai AG, Gutierrez A (2018) PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. J Exp Med 215:3094\u20133114. https:\/\/doi.org\/10.1084\/jem.20180570","journal-title":"J Exp Med"},{"key":"1563_CR10","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ni.2868","volume":"15","author":"A Arvey","year":"2014","unstructured":"Arvey A, Van Der Veeken J, Samstein RM, Feng Y, Stamatoyannopoulos JA, Rudensky AY (2014) Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 in regulatory T cells. Nat Immunol 15:580\u2013587","journal-title":"Nat Immunol"},{"key":"1563_CR11","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/ncb1403","volume":"8","author":"V Azuara","year":"2006","unstructured":"Azuara V, Perry P, Sauer S, Spivakov M, J\u00f8rgensen HF, John RM, Gouti M, Casanova M, Warnes G, Merkenschlager M, Fisher AG (2006) Chromatin signatures of pluripotent cell lines. Nat Cell Biol 8:532\u2013538. https:\/\/doi.org\/10.1038\/ncb1403","journal-title":"Nat Cell Biol"},{"key":"1563_CR12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.isci.2018.03.009","volume":"2","author":"MY Balkhi","year":"2018","unstructured":"Balkhi MY, Wittmann G, Xiong F, Junghans RP (2018) YY1 upregulates checkpoint receptors and downregulates type I cytokines in exhausted, chronically stimulated human T cells. Iscience 2:105\u2013122","journal-title":"Iscience"},{"key":"1563_CR13","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/nsmb.2434","volume":"19","author":"C Ballar\u00e9","year":"2012","unstructured":"Ballar\u00e9 C, Lange M, Lapinaite A, Martin GM, Morey L, Pascual G, Liefke R, Simon B, Shi Y, Gozani O (2012) Phf19 links methylated Lys36 of histone H3 to regulation of polycomb activity. Nat Struct Mol Biol 19:1257\u20131265","journal-title":"Nat Struct Mol Biol"},{"key":"1563_CR14","doi-asserted-by":"crossref","unstructured":"Bao Q, Kumar A, Wu D, Zhou J (2024) Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics. Drug Discov Today:103986","DOI":"10.1016\/j.drudis.2024.103986"},{"key":"1563_CR15","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.ccr.2013.04.011","volume":"23","author":"W B\u00e9guelin","year":"2013","unstructured":"B\u00e9guelin W, Popovic R, Teater M, Jiang Y, Bunting KL, Rosen M, Shen H, Yang SN, Wang L, Ezponda T (2013) EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23:677\u2013692","journal-title":"Cancer Cell"},{"key":"1563_CR16","first-page":"3914","volume":"123","author":"T Berg","year":"2014","unstructured":"Berg T, Thoene S, Yap D, Wee T, Schoeler N, Rosten P, Lim E, Bilenky M, Mungall AJ, Oellerich T (2014) A transgenic mouse model demonstrating the oncogenic role of mutations in the polycomb-group gene EZH2 in lymphomagenesis. Blood J Am Soc Hematol 123:3914\u20133924","journal-title":"Blood J Am Soc Hematol"},{"key":"1563_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.cell.2006.02.041","volume":"125","author":"BE Bernstein","year":"2006","unstructured":"Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ, Cuff J, Fry B, Meissner A, Wernig M, Plath K, Jaenisch R, Wagschal A, Feil R, Schreiber SL, Lander ES (2006) A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125:315\u2013326. https:\/\/doi.org\/10.1016\/j.cell.2006.02.041","journal-title":"Cell"},{"key":"1563_CR18","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.tplants.2021.06.006","volume":"26","author":"T Bieluszewski","year":"2021","unstructured":"Bieluszewski T, Xiao J, Yang Y, Wagner D (2021) PRC2 activity, recruitment, and silencing: a comparative perspective. Trends Plant Sci 26:1186\u2013119","journal-title":"Trends Plant Sci"},{"key":"1563_CR19","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nature16496","volume":"529","author":"AN Boettiger","year":"2016","unstructured":"Boettiger AN, Bintu B, Moffitt JR, Wang S, Beliveau BJ, Fudenberg G, Imakaev M, Mirny LA, Wu C-t, Zhuang X (2016) Super-resolution imaging reveals distinct chromatin folding for different epigenetic states. Nature 529:418\u2013422. https:\/\/doi.org\/10.1038\/nature16496","journal-title":"Nature"},{"key":"1563_CR20","doi-asserted-by":"crossref","unstructured":"Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI, Levine SS, Wernig M, Tajonar A, Ray MK (2006) Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature 441:349\u2013353","DOI":"10.1038\/nature04733"},{"key":"1563_CR21","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/nrc2736","volume":"9","author":"AP Bracken","year":"2009","unstructured":"Bracken AP, Helin K (2009) Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer 9:773\u2013784","journal-title":"Nat Rev Cancer"},{"key":"1563_CR22","doi-asserted-by":"publisher","unstructured":"Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K (2003) EZH2 is downstream of the pRB\u2010E2F pathway, essential for proliferation and amplified in cancer. EMBO J. https:\/\/doi.org\/10.1038\/nrc2736","DOI":"10.1038\/nrc2736"},{"key":"1563_CR23","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1038\/nsmb.2449","volume":"19","author":"GL Brien","year":"2012","unstructured":"Brien GL, Gambero G, O\u2019connell DJ, Jerman E, Turner SA, Egan CM, Dunne EJ, Jurgens MC, Wynne K, Piao L (2012) Polycomb PHF19 binds H3K36me3 and recruits PRC2 and demethylase NO66 to embryonic stem cell genes during differentiation. Nat Struct Mol Biol 19:1273\u20131281","journal-title":"Nat Struct Mol Biol"},{"key":"1563_CR24","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1101\/gad.267930.115","volume":"29","author":"GL Brien","year":"2015","unstructured":"Brien GL, Healy E, Jerman E, Conway E, Fadda E, O\u2019Donovan D, Krivtsov AV, Rice AM, Kearney CJ, Flaus A (2015) A chromatin-independent role of polycomb-like 1 to stabilize p53 and promote cellular quiescence. Genes Dev 29:2231\u20132243","journal-title":"Genes Dev"},{"issue":"385\u2013401","key":"1563_CR25","volume":"36","author":"ML Burr","year":"2019","unstructured":"Burr ML, Sparbier CE, Chan KL, Chan Y-C, Kersbergen A, Lam EY, Azidis-Yates E, Vassiliadis D, Bell CC, Gilan O (2019) An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell 36(385\u2013401):e388","journal-title":"Cancer Cell"},{"key":"1563_CR26","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.molcel.2012.11.026","volume":"49","author":"L Cai","year":"2013","unstructured":"Cai L, Rothbart SB, Lu R, Xu B, Chen W-Y, Tripathy A, Rockowitz S, Zheng D, Patel DJ, Allis CD (2013) An H3K36 methylation-engaging Tudor motif of polycomb-like proteins mediates PRC2 complex targeting. Mol Cell 49:571\u2013582","journal-title":"Mol Cell"},{"key":"1563_CR27","doi-asserted-by":"publisher","first-page":"1276612","DOI":"10.3389\/fmolb.2023.1276612","volume":"10","author":"L Cai","year":"2023","unstructured":"Cai L, Liu B, Cao Y, Sun T, Li Y (2023) Unveiling the molecular structure and role of RBBP4\/7: implications for epigenetic regulation and cancer research. Front Mol Biosci 10:1276612. https:\/\/doi.org\/10.3389\/fmolb.2023.1276612","journal-title":"Front Mol Biosci"},{"key":"1563_CR28","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.4161\/cc.25795","volume":"12","author":"S Campbell","year":"2013","unstructured":"Campbell S, Ismail IH, Young LC, Poirier GG, Hendzel MJ (2013) Polycomb repressive complex 2 contributes to DNA double-strand break repair. Cell Cycle 12:2675\u20132683","journal-title":"Cell Cycle"},{"key":"1563_CR29","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.molcel.2004.06.020","volume":"15","author":"R Cao","year":"2004","unstructured":"Cao R, Zhang Y (2004) SUZ12 is required for both the histone methyltransferase activity and the silencing function of the EED-EZH2 complex. Mol Cell 15:57\u201367. https:\/\/doi.org\/10.1016\/j.molcel.2004.06.020","journal-title":"Mol Cell"},{"key":"1563_CR30","doi-asserted-by":"crossref","first-page":"7274","DOI":"10.1038\/onc.2008.333","volume":"27","author":"Q Cao","year":"2008","unstructured":"Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani R-S, Tomlins SA, Mehra R, Laxman B, Cao X, Kleer CG (2008) Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene 27:7274\u20137284","journal-title":"Oncogene"},{"key":"1563_CR31","doi-asserted-by":"crossref","unstructured":"Chaffer CL, Marjanovic ND, Lee T, Bell G, Kleer CG, Reinhardt F, D\u2019Alessio AC, Young RA, Weinberg RA (2013) Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 154:61\u201374","DOI":"10.1016\/j.cell.2013.06.005"},{"key":"1563_CR32","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ccr.2010.10.035","volume":"19","author":"C-J Chang","year":"2011","unstructured":"Chang C-J, Yang J-Y, Xia W, Chen C-T, Xie X, Chao C-H, Woodward WA, Hsu J-M, Hortobagyi GN, Hung M-C (2011) EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-\u03b2-catenin signaling. Cancer Cell 19:86\u2013100","journal-title":"Cancer Cell"},{"key":"1563_CR33","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s40495-017-0100-7","volume":"3","author":"Z Chen","year":"2017","unstructured":"Chen Z, Li H (2017) Novel drugs targeting the epigenome. Curr Pharmacol Rep 3:268\u2013285","journal-title":"Curr Pharmacol Rep"},{"key":"1563_CR34","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1038\/ncb2116","volume":"12","author":"S Chen","year":"2010","unstructured":"Chen S, Bohrer LR, Rai AN, Pan Y, Gan L, Zhou X, Bagchi A, Simon JA, Huang H (2010) Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol 12:1108\u20131114. https:\/\/doi.org\/10.1038\/ncb2116","journal-title":"Nat Cell Biol"},{"key":"1563_CR35","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1101\/gad.186056.111","volume":"26","author":"S Chen","year":"2012","unstructured":"Chen S, Ma J, Wu F, Xiong L-j, Ma H, Xu W, Lv R, Li X, Villen J, Gygi SP, Liu XS, Shi Y (2012) The histone H3 Lys 27 demethylase JMJD3 regulates gene expression by impacting transcriptional elongation. Genes Dev 26:1364\u20131375. https:\/\/doi.org\/10.1101\/gad.186056.111","journal-title":"Genes Dev"},{"key":"1563_CR36","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/nsmb.3488","volume":"24","author":"J Choi","year":"2017","unstructured":"Choi J, Bachmann AL, Tauscher K, Benda C, Fierz B, M\u00fcller J (2017) DNA binding by PHF1 prolongs PRC2 residence time on chromatin and thereby promotes H3K27 methylation. Nat Struct Mol Biol 24:1039\u20131047","journal-title":"Nat Struct Mol Biol"},{"key":"1563_CR37","doi-asserted-by":"crossref","first-page":"18475","DOI":"10.1073\/pnas.1012946107","volume":"107","author":"DM Chou","year":"2010","unstructured":"Chou DM, Adamson B, Dephoure NE, Tan X, Nottke AC, Hurov KE, Gygi SP, Colai\u00e1covo MP, Elledge SJ (2010) A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage. Proc Natl Acad Sci 107:18475\u201318480","journal-title":"Proc Natl Acad Sci"},{"key":"1563_CR38","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1158\/1078-0432.Ccr-23-3383","volume":"30","author":"NJ Choudhury","year":"2024","unstructured":"Choudhury NJ, Lai WV, Makhnin A, Heller G, Eng J, Li B, Preeshagul I, Santini FC, Offin M, Ng K, Paik P, Larsen C, Ginsberg MS, Lau Y, Zhang X, Baine MK, Rekhtman N, Rudin CM (2024) A phase I\/II study of valemetostat (DS-3201b), an EZH1\/2 inhibitor, in combination with irinotecan in patients with recurrent small-cell lung cancer. Clin Cancer Res 30:3697\u20133703. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-23-3383","journal-title":"Clin Cancer Res"},{"key":"1563_CR39","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1084\/jem.20101438","volume":"207","author":"NS Christophersen","year":"2010","unstructured":"Christophersen NS, Helin K (2010) Epigenetic control of embryonic stem cell fate. J Exp Med 207:2287","journal-title":"J Exp Med"},{"key":"1563_CR40","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/2159-8290.CD-13-0117","volume":"3","author":"T Clozel","year":"2013","unstructured":"Clozel T, Yang S, Elstrom RL, Tam W, Martin P, Kormaksson M, Banerjee S, Vasanthakumar A, Culjkovic B, Scott DW (2013) Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer Discov 3:1002\u20131019","journal-title":"Cancer Discov"},{"key":"1563_CR41","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nsmb.2848","volume":"21","author":"I Comet","year":"2014","unstructured":"Comet I, Helin K (2014) Revolution in the polycomb hierarchy. Nat Struct Mol Biol 21:573\u2013575","journal-title":"Nat Struct Mol Biol"},{"key":"1563_CR42","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc.2016.83","volume":"16","author":"I Comet","year":"2016","unstructured":"Comet I, Riising EM, Leblanc B, Helin K (2016) Maintaining cell identity: PRC2-mediated regulation of transcription and cancer. Nat Rev Cancer 16:803\u2013810","journal-title":"Nat Rev Cancer"},{"key":"1563_CR43","doi-asserted-by":"crossref","first-page":"13661","DOI":"10.1038\/ncomms13661","volume":"7","author":"S Cooper","year":"2016","unstructured":"Cooper S, Grijzenhout A, Underwood E, Ancelin K, Zhang T, Nesterova TB, Anil-Kirmizitas B, Bassett A, Kooistra SM, Agger K (2016) Jarid2 binds mono-ubiquitylated H2A lysine 119 to mediate crosstalk between Polycomb complexes PRC1 and PRC2. Nat Commun 7:13661","journal-title":"Nat Commun"},{"key":"1563_CR44","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/nrd2974","volume":"8","author":"RA Copeland","year":"2009","unstructured":"Copeland RA, Solomon ME, Richon VM (2009) Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discovery 8:724\u2013732. https:\/\/doi.org\/10.1038\/nrd2974","journal-title":"Nat Rev Drug Discovery"},{"key":"1563_CR45","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/s41586-020-2246-4","volume":"582","author":"JT Cortez","year":"2020","unstructured":"Cortez JT, Montauti E, Shifrut E, Gatchalian J, Zhang Y, Shaked O, Xu Y, Roth TL, Simeonov DR, Zhang Y (2020) CRISPR screen in regulatory T cells reveals modulators of Foxp3. Nature 582:416\u2013420","journal-title":"Nature"},{"key":"1563_CR46","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/nature13561","volume":"514","author":"T De Raedt","year":"2014","unstructured":"De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, Helin K, Hornick JL, Mautner V, Kehrer-Sawatzki H (2014) PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. Nature 514:247\u2013251","journal-title":"Nature"},{"key":"1563_CR47","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nature12428","volume":"501","author":"GM Delgoffe","year":"2013","unstructured":"Delgoffe GM, Woo S-R, Turnis ME, Gravano DM, Guy C, Overacre AE, Bettini ML, Vogel P, Finkelstein D, Bonnevier J (2013) Stability and function of regulatory T cells is maintained by a neuropilin-1\u2013semaphorin-4a axis. Nature 501:252\u2013256","journal-title":"Nature"},{"key":"1563_CR48","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nsmb.2669","volume":"20","author":"L Di Croce","year":"2013","unstructured":"Di Croce L, Helin K (2013) Transcriptional regulation by Polycomb group proteins. Nat Struct Mol Biol 20:1147\u2013115","journal-title":"Nat Struct Mol Biol"},{"key":"1563_CR49","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1215-2","volume":"570","author":"M Di Pilato","year":"2019","unstructured":"Di Pilato M, Kim EY, Cadilha BL, Pr\u00fc\u00dfmann JN, Nasrallah MN, Seruggia D, Usmani SM, Misale S, Zappulli V, Carrizosa E (2019) Targeting the CBM complex causes Treg cells to prime tumours for immune checkpoint therapy. Nature 570:112\u2013116","journal-title":"Nature"},{"key":"1563_CR50","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1084\/jem.20170084","volume":"215","author":"M-W Dobenecker","year":"2018","unstructured":"Dobenecker M-W, Park JS, Marcello J, McCabe MT, Gregory R, Knight SD, Rioja I, Bassil AK, Prinjha RK, Tarakhovsky A (2018) Signaling function of PRC2 is essential for TCR-driven T cell responses. J Exp Med 215:1101\u20131113","journal-title":"J Exp Med"},{"key":"1563_CR51","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/13543776.2021.1841167","volume":"31","author":"M Dockerill","year":"2021","unstructured":"Dockerill M, Gregson C, O\u2019Donovan DH (2021) Targeting PRC2 for the treatment of cancer: an updated patent review (2016\u20132020). Expert Opin Ther Pat 31:119\u2013135","journal-title":"Expert Opin Ther Pat"},{"key":"1563_CR52","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1172\/JCI57349","volume":"122","author":"C Dong","year":"2012","unstructured":"Dong C, Wu Y, Yao J, Wang Y, Yu Y, Rychahou PG, Evers BM, Zhou BP (2012) G9a interacts with snail and is critical for snail-mediated E-cadherin repression in human breast cancer. J Clin Investig 122:1469\u20131486","journal-title":"J Clin Investig"},{"key":"1563_CR53","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/onc.2012.169","volume":"32","author":"C Dong","year":"2013","unstructured":"Dong C, Wu Y, Wang Y, Wang C, Kang T, Rychahou PG, Chi Y-I, Evers BM, Zhou BP (2013) Interaction with Suv39H1 is critical for Snail-mediated E-cadherin repression in breast cancer. Oncogene 32:1351\u20131362","journal-title":"Oncogene"},{"key":"1563_CR54","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/01.HS9.0000563668.61800.da","volume":"3","author":"C-X Du","year":"2019","unstructured":"Du C-X, Yu T-T, Liu L-T, Xu J, Li Z-Q, Yu Z, Zhan F-H, Ma X-K, Qiu L-G, Hao M (2019) PS1347 PHF19 INDUCES EZH2 PHOSPHORYLATION AND PROMOTES DRUG RESISTANCE IN MULTIPLE MYELOMA. HemaSphere 3:615. https:\/\/doi.org\/10.1097\/01.HS9.0000563668.61800.da","journal-title":"HemaSphere"},{"key":"1563_CR55","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1158\/1538-7445.AM2019-2363","volume":"79","author":"TJ DuCote","year":"2019","unstructured":"DuCote TJ, Brainson CF (2019) Targeting squamous lung tumor heterogeneity with EZH2 inhibition to improve immunotherapy responses. Can Res 79:2363\u20132363","journal-title":"Can Res"},{"key":"1563_CR56","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.molcel.2014.05.015","volume":"54","author":"H Easwaran","year":"2014","unstructured":"Easwaran H, Tsai H-C, Baylin SB (2014) Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. Mol Cell 54:716\u2013727","journal-title":"Mol Cell"},{"key":"1563_CR57","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.it.2019.02.004","volume":"40","author":"AA Emran","year":"2019","unstructured":"Emran AA, Chatterjee A, Rodger EJ, Tiffen JC, Gallagher SJ, Eccles MR, Hersey P (2019) Targeting DNA methylation and EZH2 activity to oercome melanoma resistance to immunotherapy. Trends Immunol 40:328\u2013344. https:\/\/doi.org\/10.1016\/j.it.2019.02.004","journal-title":"Trends Immunol"},{"key":"1563_CR58","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.tcb.2016.04.009","volume":"26","author":"M Entrevan","year":"2016","unstructured":"Entrevan M, Schuettengruber B, Cavalli G (2016) Regulation of genome architecture and function by polycomb proteins. Trends Cell Biol 26:511\u2013525. https:\/\/doi.org\/10.1016\/j.tcb.2016.04.009","journal-title":"Trends Cell Biol"},{"key":"1563_CR59","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","volume":"42","author":"T Ernst","year":"2010","unstructured":"Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV, Waghorn K, Zoi K, Ross FM, Reiter A (2010) Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42:722\u2013726","journal-title":"Nat Genet"},{"key":"1563_CR60","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.molcel.2010.02.032","volume":"38","author":"R Eskeland","year":"2010","unstructured":"Eskeland R, Leeb M, Grimes GR, Kress C, Boyle S, Sproul D, Gilbert N, Fan Y, Skoultchi AI, Wutz A, Bickmore WA (2010) Ring1B compacts chromatin structure and represses gene expression independent of histone ubiquitination. Mol Cell 38:452\u2013464. https:\/\/doi.org\/10.1016\/j.molcel.2010.02.032","journal-title":"Mol Cell"},{"key":"1563_CR61","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/jnci\/94.1.26","volume":"94","author":"M Esteller","year":"2002","unstructured":"Esteller M, Gaidano G, Goodman SN, Zagonel V, Capello D, Botto B, Rossi D, Gloghini A, Vitolo U, Carbone A (2002) Hypermethylation of the DNA repair gene O 6-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 94:26\u201332","journal-title":"J Natl Cancer Inst"},{"key":"1563_CR62","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.molcel.2013.10.030","volume":"53","author":"J Ferrari Karin","year":"2014","unstructured":"Ferrari Karin J, Scelfo A, Jammula S, Cuomo A, Barozzi I, St\u00fctzer A, Fischle W, Bonaldi T, Pasini D (2014) Polycomb-dependent H3K27me1 and H3K27me2 regulate active transcription and enhancer fidelity. Mol Cell 53:49\u201362. https:\/\/doi.org\/10.1016\/j.molcel.2013.10.030","journal-title":"Mol Cell"},{"key":"1563_CR63","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/tcr.201800091","volume":"18","author":"R Fioravanti","year":"2018","unstructured":"Fioravanti R, Stazi G, Zwergel C, Valente S, Mai A (2018) Six years (2012\u20132018) of researches on catalytic ezh2 inhibitors: the boom of the 2-pyridone compounds. Chem Rec 18:1818\u20131832","journal-title":"Chem Rec"},{"key":"1563_CR64","doi-asserted-by":"publisher","unstructured":"Flinders C, Lam L, Rubbi L, Ferrari R, Fitz-Gibbon S, Chen P-Y, Thompson M, Christofk H, Agus BD, Ruderman D, Mallick P, Pellegrini M (2016a) Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma. Genome Med 8:54. https:\/\/doi.org\/10.1186\/s13073-016-0305-0","DOI":"10.1186\/s13073-016-0305-0"},{"key":"1563_CR65","doi-asserted-by":"publisher","unstructured":"Flinders C, Lam L, Rubbi L, Ferrari R, Fitz-Gibbon S, Chen PY, Thompson M, Christofk HDBA, Ruderman D, Mallick P, Pellegrini M (2016b) Epigenetic changes mediated by polycomb repressive complex 2 and E2a are associated with drug resistance in a mouse model of lymphoma. Genome Med 8:54. https:\/\/doi.org\/10.1186\/s13073-016-0305-0","DOI":"10.1186\/s13073-016-0305-0"},{"issue":"1","key":"1563_CR66","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/jnci\/82.1.4","volume":"82","author":"J Folkman","year":"1990","unstructured":"Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82(1):4\u20137. https:\/\/doi.org\/10.1093\/jnci\/82.1.4","journal-title":"J Natl Cancer Inst"},{"key":"1563_CR67","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1126\/science.1100576","volume":"306","author":"NJ Francis","year":"2004","unstructured":"Francis NJ, Kingston RE, Woodcock CL (2004) Chromatin compaction by a polycomb group protein complex. Science 306:1574\u20131577. https:\/\/doi.org\/10.1126\/science.1100576","journal-title":"Science"},{"key":"1563_CR68","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1158\/2159-8290.Cd-21-0980","volume":"12","author":"V Gambacorta","year":"2022","unstructured":"Gambacorta V, Beretta S, Ciccimarra M, Zito L, Giannetti K, Andrisani A, Gnani D, Zanotti L, Oliveira G, Carrabba MG, Cittaro D, Merelli I, Ciceri F, Di Micco R, Vago L (2022) Integrated multiomic profiling identifies the epigenetic regulator PRC2 as a therapeutic target to counteract leukemia immune escape and relapse. Cancer Discov 12:1449\u20131461. https:\/\/doi.org\/10.1158\/2159-8290.Cd-21-0980","journal-title":"Cancer Discov"},{"key":"1563_CR69","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nm.4247","volume":"23","author":"S G\u00f6llner","year":"2017","unstructured":"G\u00f6llner S, Oellerich T, Agrawal-Singh S, Schenk T, Klein H-U, Rohde C, Pabst C, Sauer T, Lerdrup M, Tavor S (2017a) Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia. Nat Med 23:69\u201378","journal-title":"Nat Med"},{"key":"1563_CR70","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1172\/JCI99760","volume":"128","author":"S Goswami","year":"2018","unstructured":"Goswami S, Apostolou I, Zhang J, Skepner J, Anandhan S, Zhang X, Xiong L, Trojer P, Aparicio A, Subudhi SK (2018a) Modulation of EZH2 expression in T cells improves efficacy of anti\u2013CTLA-4 therapy. J Clin Investig 128:3813\u20133818","journal-title":"J Clin Investig"},{"key":"1563_CR71","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1158\/1078-0432.Ccr-18-3133","volume":"25","author":"MM Gounder","year":"2019","unstructured":"Gounder MM, Zhu G, Roshal L, Lis E, Daigle SR, Blakemore SJ, Michaud NR, Hameed M, Hollmann TJ (2019) Immunologic correlates of the abscopal effect in a SMARCB1\/INI1-negative poorly differentiated chordoma after EZH2 inhibition and radiotherapy. Clin Cancer Res 25:2064\u20132071. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-3133","journal-title":"Clin Cancer Res"},{"key":"1563_CR72","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/s1470-2045(20)30451-4","volume":"21","author":"M Gounder","year":"2020","unstructured":"Gounder M, Sch\u00f6ffski P, Jones RL, Agulnik M, Cote GM, Villalobos VM, Attia S, Chugh R, Chen TW, Jahan T, Loggers ET, Gupta A, Italiano A, Demetri GD, Ratan R, Davis LE, Mir O, Dileo P, Van Tine BA, Pressey JG, Lingaraj T, Rajarethinam A, Sierra L, Agarwal S, Stacchiotti S (2020) Tazemetostat in advanced epithelioid sarcoma with loss of INI1\/SMARCB1: an international, open-label, phase 2 basket study. Lancet Oncol 21:1423\u20131432. https:\/\/doi.org\/10.1016\/s1470-2045(20)30451-4","journal-title":"Lancet Oncol"},{"key":"1563_CR73","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1080\/10428194.2018.1430795","volume":"59","author":"N Gulati","year":"2018","unstructured":"Gulati N, B\u00e9guelin W, Giulino-Roth L (2018) Enhancer of zeste homolog 2 (EZH2) inhibitors. Leuk Lymphoma 59:1574\u20131585","journal-title":"Leuk Lymphoma"},{"key":"1563_CR74","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ni.3125","volume":"16","author":"M Gunawan","year":"2015","unstructured":"Gunawan M, Venkatesan N, Loh JT, Wong JF, Berger H, Neo WH, Li LYJ, La Win MK, Yau YH, Guo T (2015) The methyltransferase Ezh2 controls cell adhesion and migration through direct methylation of the extranuclear regulatory protein talin. Nat Immunol 16:505\u2013516","journal-title":"Nat Immunol"},{"key":"1563_CR75","doi-asserted-by":"crossref","unstructured":"Guo W, Wang Y, Yang M, Wang Z, Wang Y, Chaurasia S, Wu Z, Zhang M, Yadav GS, Rathod S (2021) LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance. Sci Adv 7:eabb3555","DOI":"10.1126\/sciadv.abb3555"},{"key":"1563_CR76","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.str.2007.08.007","volume":"15","author":"Z Han","year":"2007","unstructured":"Han Z, Xing X, Hu M, Zhang Y, Liu P, Chai J (2007) Structural basis of EZH2 recognition by EED. Structure 15:1306\u20131315. https:\/\/doi.org\/10.1016\/j.str.2007.08.007","journal-title":"Structure"},{"key":"1563_CR77","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D (2022) Hallmarks of cancer: new dimensions. Cancer Discov 12:31\u201346","journal-title":"Cancer Discov"},{"key":"1563_CR78","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1101\/gad.173930.111","volume":"26","author":"A He","year":"2012","unstructured":"He A, Shen X, Ma Q, Cao J, von Gise A, Zhou P, Wang G, Marquez VE, Orkin SH, Pu WT (2012) PRC2 directly methylates GATA4 and represses its transcriptional activity. Genes Dev 26:37\u201342","journal-title":"Genes Dev"},{"key":"1563_CR79","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature12751","volume":"502","author":"K Helin","year":"2013","unstructured":"Helin K, Dhanak D (2013) Chromatin proteins and modifications as drug targets. Nature 502:480\u2013488","journal-title":"Nature"},{"key":"1563_CR80","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00323-08","author":"N Herranz","year":"2008","unstructured":"Herranz N, Pasini D, VcM D\u00edaz, Franc\u00ed C, Gutierrez A, Dave N, Escriva M, Hernandez-Munoz I, Di Croce L, Helin K (2008) Polycomb complex 2 is required for E-cadherin repression by the Snail1 transcription factor. Mol Cell Biol. https:\/\/doi.org\/10.1128\/MCB.00323-08","journal-title":"Mol Cell Biol"},{"key":"1563_CR81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13148-018-0554-4","volume":"10","author":"L Herviou","year":"2018","unstructured":"Herviou L, Kassambara A, Boireau S, Robert N, Requirand G, M\u00fcller-Tidow C, Vincent L, Seckinger A, Goldschmidt H, Cartron G (2018) PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs. Clin Epigenetics 10:1\u201318","journal-title":"Clin Epigenetics"},{"key":"1563_CR82","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.molcel.2019.07.031","volume":"76","author":"JW H\u00f8jfeldt","year":"2019","unstructured":"H\u00f8jfeldt JW, Hedehus L, Laugesen A, Tatar T, Wiehle L, Helin K (2019) Non-core subunits of the PRC2 complex are collectively required for its target-site specificity. Mol Cell 76:423-436.e423. https:\/\/doi.org\/10.1016\/j.molcel.2019.07.031","journal-title":"Mol Cell"},{"key":"1563_CR83","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.01435-07","author":"Z Hou","year":"2008","unstructured":"Hou Z, Peng H, Ayyanathan K, Yan K-P, Langer EM, Longmore GD, Rauscher FJ III (2008) The LIM protein AJUBA recruits protein arginine methyltransferase 5 to mediate SNAIL-dependent transcriptional repression. Mol Cell Biol. https:\/\/doi.org\/10.1128\/MCB.01435-07","journal-title":"Mol Cell Biol"},{"key":"1563_CR84","doi-asserted-by":"publisher","first-page":"788","DOI":"10.4161\/cbt.10.8.12913","volume":"10","author":"S Hu","year":"2010","unstructured":"Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J, Xiao L, Wang Z (2010) Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther 10:788\u2013795. https:\/\/doi.org\/10.4161\/cbt.10.8.12913","journal-title":"Cancer Biol Ther"},{"key":"1563_CR85","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1038\/emm.2017.11","volume":"49","author":"K Hyun","year":"2017","unstructured":"Hyun K, Jeon J, Park K, Kim J (2017) Writing, erasing and reading histone lysine methylations. Exp Mol Med 49:e324\u2013e324","journal-title":"Exp Mol Med"},{"key":"1563_CR86","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.molcel.2010.08.013","volume":"39","author":"D Iliopoulos","year":"2010","unstructured":"Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K (2010) Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 39:761\u2013772","journal-title":"Mol Cell"},{"key":"1563_CR87","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1111\/cas.15040","volume":"112","author":"K Izutsu","year":"2021","unstructured":"Izutsu K, Ando K, Nishikori M, Shibayama H, Teshima T, Kuroda J, Kato K, Imaizumi Y, Nosaka K, Sakai R, Hojo S, Nakanishi T, Rai S (2021) Phase II study of tazemetostat for relapsed or refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan. Cancer Sci 112:3627\u20133635. https:\/\/doi.org\/10.1111\/cas.15040","journal-title":"Cancer Sci"},{"key":"1563_CR88","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1182\/blood.2022016862","volume":"141","author":"K Izutsu","year":"2023","unstructured":"Izutsu K, Makita S, Nosaka K, Yoshimitsu M, Utsunomiya A, Kusumoto S, Morishima S, Tsukasaki K, Kawamata T, Ono T, Rai S, Katsuya H, Ishikawa J, Yamada H, Kato K, Tachibana M, Kakurai Y, Adachi N, Tobinai K, Yonekura K, Ishitsuka K (2023) An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia\/lymphoma. Blood 141:1159\u20131168. https:\/\/doi.org\/10.1182\/blood.2022016862","journal-title":"Blood"},{"key":"1563_CR89","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-024-03834-9","author":"K Izutsu","year":"2024","unstructured":"Izutsu K, Ando K, Nishikori M, Shibayama H, Goto H, Kuroda J, Kato K, Imaizumi Y, Nosaka K, Sakai R, Abe M, Hojo S, Nakanishi T, Rai S (2024) Tazemetostat for relapsed\/refractory B-cell non-Hodgkin lymphoma with EZH2 mutation in Japan: 3-year follow-up for a phase II study. Int J Hematol. https:\/\/doi.org\/10.1007\/s12185-024-03834-9","journal-title":"Int J Hematol"},{"key":"1563_CR90","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nsmb.2833","volume":"21","author":"R Kalb","year":"2014","unstructured":"Kalb R, Latwiel S, Baymaz HI, Jansen PW, M\u00fcller CW, Vermeulen M, M\u00fcller J (2014) Histone H2A monoubiquitination promotes histone H3 methylation in polycomb repression. Nat Struct Mol Biol 21:569\u2013571","journal-title":"Nat Struct Mol Biol"},{"key":"1563_CR91","first-page":"172","volume":"7","author":"T Karantanos","year":"2016","unstructured":"Karantanos T, Christofides A, Bardhan K, Li L, Boussiotis VA (2016) Regulation of T cell differentiation and function by EZH2. Front Immunol 7:172","journal-title":"Front Immunol"},{"key":"1563_CR92","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1158\/0008-5472.Can-24-0398","volume":"84","author":"PJ Keller","year":"2024","unstructured":"Keller PJ, Adams EJ, Wu R, C\u00f4t\u00e9 A, Arora S, Cantone N, Meyer R, Mertz JA, Gehling V, Cui J, Stuckey JI, Khanna A, Zhao F, Chen Z, Yu Z, Cummings RT, Taimi M, Lakhani NJ, Rasco D, Gutierrez M, Duska L, Devitt M, Rippley R, Levell J, Truong J, Wang J, Sun K, Trojer P (2024) Comprehensive target engagement by the EZH2 inhibitor tulmimetostat allows for targeting of ARID1A mutant cancers. Cancer Res 84:2501\u20132517. https:\/\/doi.org\/10.1158\/0008-5472.Can-24-0398","journal-title":"Cancer Res"},{"key":"1563_CR93","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/leu.2013.80","volume":"27","author":"S Khan","year":"2013","unstructured":"Khan S, Jankowska A, Mahfouz R, Dunbar A, Sugimoto Y, Hosono N, Hu Z, Cheriyath V, Vatolin S, Przychodzen B (2013) Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies. Leukemia 27:1301\u20131309","journal-title":"Leukemia"},{"key":"1563_CR94","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nchembio.1331","volume":"9","author":"W Kim","year":"2013","unstructured":"Kim W, Bird GH, Neff T, Guo G, Kerenyi MA, Walensky LD, Orkin SH (2013) Targeted disruption of the EZH2\u2013EED complex inhibits EZH2-dependent cancer. Nat Chem Biol 9:643\u2013650","journal-title":"Nat Chem Biol"},{"key":"1563_CR95","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.it.2020.08.010","volume":"41","author":"H-J Kim","year":"2020","unstructured":"Kim H-J, Cantor H, Cosmopoulos K (2020) Overcoming immune checkpoint blockade resistance via EZH2 inhibition. Trends Immunol 41:948\u2013963","journal-title":"Trends Immunol"},{"key":"1563_CR96","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.coi.2017.10.002","volume":"49","author":"Y Kitagawa","year":"2017","unstructured":"Kitagawa Y, Sakaguchi S (2017) Molecular control of regulatory T cell development and function. Curr Opin Immunol 49:64\u201370","journal-title":"Curr Opin Immunol"},{"key":"1563_CR97","doi-asserted-by":"crossref","first-page":"11606","DOI":"10.1073\/pnas.1933744100","volume":"100","author":"CG Kleer","year":"2003","unstructured":"Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci 100:11606\u201311611","journal-title":"Proc Natl Acad Sci"},{"key":"1563_CR98","doi-asserted-by":"crossref","first-page":"7922","DOI":"10.1073\/pnas.1303800110","volume":"110","author":"SK Knutson","year":"2013","unstructured":"Knutson SK, Warholic NM, Wigle TJ, Klaus CR, Allain CJ, Raimondi A, Porter Scott M, Chesworth R, Moyer MP, Copeland RA (2013) Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc Natl Acad Sci 110:7922\u20137927","journal-title":"Proc Natl Acad Sci"},{"key":"1563_CR99","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1021\/cb400133j","volume":"8","author":"KD Konze","year":"2013","unstructured":"Konze KD, Ma A, Li F, Barsyte-Lovejoy D, Parton T, MacNevin CJ, Liu F, Gao C, Huang X-P, Kuznetsova E (2013) An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1. ACS Chem Biol 8:1324\u20131334","journal-title":"ACS Chem Biol"},{"key":"1563_CR100","doi-asserted-by":"publisher","first-page":"21396","DOI":"10.1038\/s41598-021-00889-0","volume":"11","author":"Y Kusakabe","year":"2021","unstructured":"Kusakabe Y, Chiba T, Oshima M, Koide S, Rizq O, Aoyama K, Ao J, Kaneko T, Kanzaki H, Kanayama K, Maeda T, Saito T, Nakagawa R, Kobayashi K, Kiyono S, Nakamura M, Ogasawara S, Suzuki E, Nakamoto S, Yasui S, Mikata R, Muroyama R, Kanda T, Maruyama H, Kato J, Mimura N, Ma A, Jin J, Zen Y, Otsuka M, Kaneda A, Iwama A, Kato N (2021) EZH1\/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma. Sci Rep 11:21396. https:\/\/doi.org\/10.1038\/s41598-021-00889-0","journal-title":"Sci Rep"},{"key":"1563_CR101","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.devcel.2008.01.005","volume":"14","author":"EM Langer","year":"2008","unstructured":"Langer EM, Feng Y, Zhaoyuan H, Rauscher FJ, Kroll KL, Longmore GD (2008) Ajuba LIM proteins are snail\/slug corepressors required for neural crest development in Xenopus. Dev Cell 14:424\u2013436","journal-title":"Dev Cell"},{"key":"1563_CR102","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.stem.2014.05.006","volume":"14","author":"A Laugesen","year":"2014","unstructured":"Laugesen A, Helin K (2014) Chromatin repressive complexes in stem cells, development, and cancer. Cell Stem Cell 14:735\u2013751","journal-title":"Cell Stem Cell"},{"key":"1563_CR103","doi-asserted-by":"publisher","unstructured":"Laugesen A, H\u00f8jfeldt JW, Helin K (2016) Role of the polycomb repressive complex 2 (PRC2) in transcriptional regulation and cancer. Cold Spring Harb Perspect Med 6. https:\/\/doi.org\/10.1101\/cshperspect.a026575","DOI":"10.1101\/cshperspect.a026575"},{"key":"1563_CR104","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026575","volume":"6","author":"A Laugesen","year":"2016","unstructured":"Laugesen A, H\u00f8jfeldt JW, Helin K (2016b) Role of the polycomb repressive complex 2 (PRC2) in transcriptional regulation and cancer. Cold Spring Harb Perspect Med 6:a026575","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1563_CR105","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cell.2006.02.043","volume":"125","author":"TI Lee","year":"2006","unstructured":"Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, Chevalier B, Johnstone SE, Cole MF, Isono K-i (2006) Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125:301\u2013313","journal-title":"Cell"},{"key":"1563_CR106","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.molcel.2012.09.004","volume":"48","author":"JM Lee","year":"2012","unstructured":"Lee JM, Lee JS, Kim H, Kim K, Park H, Kim J-Y, Lee SH, Kim IS, Kim J, Lee M (2012) EZH2 generates a methyl degron that is recognized by the DCAF1\/DDB1\/CUL4 E3 ubiquitin ligase complex. Mol Cell 48:572\u2013586","journal-title":"Mol Cell"},{"key":"1563_CR107","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/ng.3095","volume":"46","author":"W Lee","year":"2014","unstructured":"Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada CN, Lin M, Zhu S, Cao Z, Liang Y, Sboner A (2014) PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet 46:1227\u20131232","journal-title":"Nat Genet"},{"issue":"435\u2013448","key":"1563_CR108","volume":"70","author":"C-H Lee","year":"2018","unstructured":"Lee C-H, Holder M, Grau D, Salda\u00f1a-Meyer R, Yu J-R, Ganai RA, Zhang J, Wang M, LeRoy G, Dobenecker M-W (2018) Distinct stimulatory mechanisms regulate the catalytic activity of polycomb repressive complex 2. Mol Cell 70(435\u2013448):e435","journal-title":"Mol Cell"},{"key":"1563_CR109","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1038\/s41467-019-12811-4","volume":"10","author":"P Lhoumaud","year":"2019","unstructured":"Lhoumaud P, Badri S, Rodriguez-Hernaez J, Sakellaropoulos T, Sethia G, Kloetgen A, Cornwell M, Bhattacharyya S, Ay F, Bonneau R (2019) NSD2 overexpression drives clustered chromatin and transcriptional changes in a subset of insulated domains. Nat Commun 10:4843","journal-title":"Nat Commun"},{"key":"1563_CR110","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1101\/gad.1886410","volume":"24","author":"G Li","year":"2010","unstructured":"Li G, Margueron R, Ku M, Chambon P, Bernstein BE, Reinberg D (2010) Jarid2 and PRC2, partners in regulating gene expression. Genes Dev 24:368\u2013380","journal-title":"Genes Dev"},{"key":"1563_CR111","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature23881","volume":"549","author":"H Li","year":"2017","unstructured":"Li H, Liefke R, Jiang J, Kurland JV, Tian W, Deng P, Zhang W, He Q, Patel DJ, Bulyk ML (2017) Polycomb-like proteins link the PRC2 complex to CpG islands. Nature 549:287\u2013291","journal-title":"Nature"},{"key":"1563_CR112","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1158\/2159-8290.CD-20-1771","volume":"12","author":"J Li","year":"2022","unstructured":"Li J, Hlavka-Zhang J, Shrimp JH, Piper C, Dup\u00e9r\u00e9-Rich\u00e9r D, Roth JS, Jing D, Casellas Rom\u00e1n HL, Troche C, Swaroop A (2022) PRC2 inhibitors overcome glucocorticoid resistance driven by NSD2 mutation in pediatric acute lymphoblastic leukemia. Cancer Discov 12:186\u2013203","journal-title":"Cancer Discov"},{"key":"1563_CR113","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1038\/emboj.2010.63","volume":"29","author":"Y Lin","year":"2010","unstructured":"Lin Y, Wu Y, Li J, Dong C, Ye X, Chi YI, Evers BM, Zhou BP (2010) The SNAG domain of Snail1 functions as a molecular hook for recruiting lysine-specific demethylase 1. EMBO J 29:1803\u20131816","journal-title":"EMBO J"},{"key":"1563_CR114","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1039\/d1md00274k","volume":"13","author":"KL Liu","year":"2022","unstructured":"Liu KL, Zhu K, Zhang H (2022) An overview of the development of EED inhibitors to disable the PRC2 function. RSC Med Chem 13:39\u201353. https:\/\/doi.org\/10.1039\/d1md00274k","journal-title":"RSC Med Chem"},{"key":"1563_CR115","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/0008-5472.CAN-06-3700","volume":"67","author":"C Lu","year":"2007","unstructured":"Lu C, Bonome T, Li Y, Kamat AA, Han LY, Schmandt R, Coleman RL, Gershenson DM, Jaffe RB, Birrer MJ (2007) Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Can Res 67:1757\u20131768","journal-title":"Can Res"},{"key":"1563_CR116","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ccr.2010.06.016","volume":"18","author":"C Lu","year":"2010","unstructured":"Lu C, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A (2010) Regulation of tumor angiogenesis by EZH2. Cancer Cell 18:185\u2013197","journal-title":"Cancer Cell"},{"key":"1563_CR117","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12943-020-01197-3","volume":"19","author":"Y Lu","year":"2020","unstructured":"Lu Y, Chan Y-T, Tan H-Y, Li S, Wang N, Feng Y (2020) Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol Cancer 19:79. https:\/\/doi.org\/10.1186\/s12943-020-01197-3","journal-title":"Mol Cancer"},{"key":"1563_CR118","first-page":"1","volume":"9","author":"D-N Ma","year":"2016","unstructured":"Ma D-N, Chai Z-T, Zhu X-D, Zhang N, Zhan D-H, Ye B-G, Wang C-H, Qin C-D, Zhao Y-M, Zhu W-P (2016) MicroRNA-26a suppresses epithelial-mesenchymal transition in human hepatocellular carcinoma by repressing enhancer of zeste homolog 2. J Hematol Oncol 9:1\u201310","journal-title":"J Hematol Oncol"},{"key":"1563_CR119","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1158\/2159-8290.Cd-17-0841","volume":"8","author":"HB Maganti","year":"2018","unstructured":"Maganti HB, Jrade H, Cafariello C, Manias Rothberg JL, Porter CJ, Yockell-Leli\u00e8vre J, Battaion HL, Khan ST, Howard JP, Li Y, Grzybowski AT, Sabri E, Ruthenburg AJ, Dilworth FJ, Perkins TJ, Sabloff M, Ito CY, Stanford WL (2018) Targeting the MTF2\u2013MDM2 axis sensitizes refractory acute myeloid leukemia to chemotherapy. Cancer Discov 8:1376\u20131389. https:\/\/doi.org\/10.1158\/2159-8290.Cd-17-0841","journal-title":"Cancer Discov"},{"key":"1563_CR120","doi-asserted-by":"crossref","first-page":"E3735","DOI":"10.1073\/pnas.1602079113","volume":"113","author":"S Mahara","year":"2016","unstructured":"Mahara S, Lee PL, Feng M, Tergaonkar V, Chng WJ, Yu Q (2016) HIFI-\u03b1 activation underlies a functional switch in the paradoxical role of Ezh2\/PRC2 in breast cancer. Proc Natl Acad Sci 113:E3735\u2013E3744","journal-title":"Proc Natl Acad Sci"},{"key":"1563_CR121","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0060093","volume":"6","author":"IJ Majewski","year":"2008","unstructured":"Majewski IJ, Blewitt ME, de Graaf CA, McManus EJ, Bahlo M, Hilton AA, Hyland CD, Smyth GK, Corbin JE, Metcalf D (2008) Polycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activity. PLoS Biol 6:e93","journal-title":"PLoS Biol"},{"key":"1563_CR122","first-page":"731","volume":"116","author":"IJ Majewski","year":"2010","unstructured":"Majewski IJ, Ritchie ME, Phipson B, Corbin J, Pakusch M, Ebert A, Busslinger M, Koseki H, Hu Y, Smyth GK (2010) Opposing roles of polycomb repressive complexes in hematopoietic stem and progenitor cells. Blood J Am Soc Hematol 116:731\u2013739","journal-title":"Blood J Am Soc Hematol"},{"key":"1563_CR123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/gb-2013-14-12-r144","volume":"14","author":"GG Malouf","year":"2013","unstructured":"Malouf GG, Taube JH, Lu Y, Roysarkar T, Panjarian S, Estecio MR, Jelinek J, Yamazaki J, Raynal NJ, Long H (2013) Architecture of epigenetic reprogramming following Twist1-mediated epithelial-mesenchymal transition. Genome Biol 14:1\u201317","journal-title":"Genome Biol"},{"key":"1563_CR124","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature09784","volume":"469","author":"R Margueron","year":"2011","unstructured":"Margueron R, Reinberg D (2011) The polycomb complex PRC2 and its mark in life. Nature 469:343\u2013349","journal-title":"Nature"},{"key":"1563_CR125","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.molcel.2008.11.004","volume":"32","author":"R Margueron","year":"2008","unstructured":"Margueron R, Li G, Sarma K, Blais A, Zavadil J, Woodcock CL, Dynlacht BD, Reinberg D (2008) Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. Mol Cell 32:503\u2013518. https:\/\/doi.org\/10.1016\/j.molcel.2008.11.004","journal-title":"Mol Cell"},{"key":"1563_CR126","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3892\/ijo.2020.5122","volume":"57","author":"CJ Martin","year":"2020","unstructured":"Martin CJ, Moorehead RA (2020) Polycomb repressor complex 2 function in breast cancer (Review). Int J Oncol 57:1085\u20131094. https:\/\/doi.org\/10.3892\/ijo.2020.5122","journal-title":"Int J Oncol"},{"key":"1563_CR127","first-page":"629","volume":"125","author":"A Mayle","year":"2015","unstructured":"Mayle A, Yang L, Rodriguez B, Zhou T, Chang E, Curry CV, Challen GA, Li W, Wheeler D, Rebel VI (2015) Dnmt3a loss predisposes murine hematopoietic stem cells to malignant transformation. Blood J Am Soc Hematol 125:629\u2013638","journal-title":"Blood J Am Soc Hematol"},{"key":"1563_CR128","doi-asserted-by":"crossref","unstructured":"McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, III AD, Diaz E, LaFrance LV (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492(7427):108\u201312","DOI":"10.1038\/nature11606"},{"key":"1563_CR129","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/0008-5472.CAN-06-2029","volume":"67","author":"KM McGarvey","year":"2007","unstructured":"McGarvey KM, Greene E, Fahrner JA, Jenuwein T, Baylin SB (2007) DNA methylation and complete transcriptional silencing of cancer genes persist after depletion of EZH2. Can Res 67:5097\u20135102","journal-title":"Can Res"},{"key":"1563_CR130","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/s41419-021-04407-y","volume":"12","author":"IK Mieczkowska","year":"2021","unstructured":"Mieczkowska IK, Pantelaiou-Prokaki G, Prokakis E, Schmidt GE, M\u00fcller-Kirschbaum LC, Werner M, Sen M, Velychko T, Jannasch K, Dullin C (2021) Decreased PRC2 activity supports the survival of basal-like breast cancer cells to cytotoxic treatments. Cell Death Dis 12:1118","journal-title":"Cell Death Dis"},{"key":"1563_CR131","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nm.2100","volume":"16","author":"J Min","year":"2010","unstructured":"Min J, Zaslavsky A, Fedele G, McLaughlin SK, Reczek EE, De Raedt T, Guney I, Strochlic DE, MacConaill LE, Beroukhim R (2010) An oncogene\u2013tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-\u03baB. Nat Med 16:286\u2013294","journal-title":"Nat Med"},{"key":"1563_CR132","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/nm.4293","volume":"23","author":"F Mohammad","year":"2017","unstructured":"Mohammad F, Weissmann S, Leblanc B, Pandey DP, H\u00f8jfeldt JW, Comet I, Zheng C, Johansen JV, Rapin N, Porse BT, Tvardovskiy A, Jensen ON, Olaciregui NG, Lavarino C, Su\u00f1ol M, de Torres C, Mora J, Carcaboso AM, Helin K (2017) EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat Med 23:483\u2013492. https:\/\/doi.org\/10.1038\/nm.4293","journal-title":"Nat Med"},{"key":"1563_CR133","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1517\/13543784.2015.1051220","volume":"24","author":"RL Momparler","year":"2015","unstructured":"Momparler RL, C\u00f4t\u00e9 S (2015) Targeting of cancer stem cells by inhibitors of DNA and histone methylation. Expert Opin Investig Drugs 24:1031\u20131043. https:\/\/doi.org\/10.1517\/13543784.2015.1051220","journal-title":"Expert Opin Investig Drugs"},{"key":"1563_CR134","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","volume":"42","author":"RD Morin","year":"2010","unstructured":"Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F (2010) Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42:181\u2013185","journal-title":"Nat Genet"},{"key":"1563_CR135","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","volume":"476","author":"RD Morin","year":"2011","unstructured":"Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, Johnson NA, Severson TM, Chiu R, Field M (2011) Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 476:298\u2013303","journal-title":"Nature"},{"key":"1563_CR136","doi-asserted-by":"crossref","first-page":"13805","DOI":"10.1074\/jbc.R117.800367","volume":"293","author":"LE Moritz","year":"2018","unstructured":"Moritz LE, Trievel RC (2018) Structure, mechanism, and regulation of polycomb-repressive complex 2. J Biol Chem 293:13805\u201313814","journal-title":"J Biol Chem"},{"key":"1563_CR137","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1158\/0008-5472.CAN-15-1938","volume":"76","author":"N Nagarsheth","year":"2016","unstructured":"Nagarsheth N, Peng D, Kryczek I, Wu K, Li W, Zhao E, Zhao L, Wei S, Frankel T, Vatan L (2016) PRC2 epigenetically silences Th1-type chemokines to suppress effector T-cell trafficking in colon cancer. Can Res 76:275\u2013282","journal-title":"Can Res"},{"key":"1563_CR138","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-9-151","volume":"9","author":"S Nagel","year":"2010","unstructured":"Nagel S, Venturini L, Marquez VE, Meyer C, Kaufmann M, Scherr M, MacLeod RA, Drexler HG (2010) Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK\/T-cell lines. Mol Cancer 9:1\u201312","journal-title":"Mol Cancer"},{"key":"1563_CR139","doi-asserted-by":"crossref","first-page":"5028","DOI":"10.1073\/pnas.1202258109","volume":"109","author":"T Neff","year":"2012","unstructured":"Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, Xie H, Orkin SH, Armstrong SA (2012) Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci 109:5028\u20135033","journal-title":"Proc Natl Acad Sci"},{"key":"1563_CR140","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/ng.620","volume":"42","author":"G Nikoloski","year":"2010","unstructured":"Nikoloski G, Langemeijer SM, Kuiper RP, Knops R, Massop M, T\u00f6nnissen ER, Van der Heijden A, Scheele TN, Vandenberghe P, de Witte T (2010) Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 42:665\u2013667","journal-title":"Nat Genet"},{"key":"1563_CR141","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.2651","volume":"18","author":"P Ntziachristos","year":"2012","unstructured":"Ntziachristos P, Tsirigos A, Vlierberghe PV, Nedjic J, Trimarchi T, Flaherty MS, Ferres-Marco D, Da Ros V, Tang Z, Siegle J (2012) Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 18:298\u2013302","journal-title":"Nat Med"},{"key":"1563_CR142","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.clml.2021.12.014","volume":"22","author":"ML Palomba","year":"2022","unstructured":"Palomba ML, Cartron G, Popplewell L, Ribrag V, Westin J, Huw LY, Agarwal S, Shivhare M, Hong WJ, Raval A, Chang AC, Penuel E, Morschhauser F (2022) Combination of aezolizumab and tazemetostat in patients with relapsed\/refractory diffuse large B-cell lymphoma: results from a phase Ib study. Clin Lymphoma Myeloma Leuk 22:504\u2013512. https:\/\/doi.org\/10.1016\/j.clml.2021.12.014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1563_CR143","doi-asserted-by":"crossref","first-page":"45134","DOI":"10.18632\/oncotarget.9761","volume":"7","author":"B Pang","year":"2016","unstructured":"Pang B, Zheng X-R, Tian J-x, Gao T-h, Gu G-y, Zhang R, Fu Y-B, Pang Q, Li X-G, Liu Q (2016) EZH2 promotes metabolic reprogramming in glioblastomas through epigenetic repression of EAF2-HIF1\u03b1 signaling. Oncotarget 7:45134","journal-title":"Oncotarget"},{"key":"1563_CR144","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41422-021-00606-6","volume":"32","author":"V Parreno","year":"2022","unstructured":"Parreno V, Martinez A-M, Cavalli G (2022) Mechanisms of Polycomb group protein function in cancer. Cell Res 32:231\u2013253","journal-title":"Cell Res"},{"key":"1563_CR145","doi-asserted-by":"publisher","first-page":"3769","DOI":"10.1128\/MCB.01432-06","volume":"27","author":"D Pasini","year":"2007","unstructured":"Pasini D, Bracken AP, Hansen JB, Capillo M, Helin K (2007) The polycomb group protein Suz12 is required for embryonic stem cell differentiation. Mol Cell Biol 27:3769\u20133779. https:\/\/doi.org\/10.1128\/MCB.01432-06","journal-title":"Mol Cell Biol"},{"key":"1563_CR146","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","volume":"43","author":"L Pasqualucci","year":"2011","unstructured":"Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A, Wells VA, Grunn A, Messina M, Elliot O (2011) Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 43:830\u2013837","journal-title":"Nat Genet"},{"key":"1563_CR147","doi-asserted-by":"crossref","unstructured":"Peinado H, Ballestar E, Esteller M, Cano A (2004) Snail mediates E-cadherin repression by the recruitment of the Sin3A\/histone deacetylase 1 (HDAC1)\/HDAC2 complex. Mol Cell Biol","DOI":"10.1128\/MCB.24.1.306-319.2004"},{"key":"1563_CR148","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/modpathol.2017.97","volume":"30","author":"M Pekmezci","year":"2017","unstructured":"Pekmezci M, Cuevas-Ocampo AK, Perry A, Horvai AE (2017) Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors. Mod Pathol 30:1710\u20131719. https:\/\/doi.org\/10.1038\/modpathol.2017.97","journal-title":"Mod Pathol"},{"key":"1563_CR149","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.cell.2009.12.002","volume":"139","author":"JC Peng","year":"2009","unstructured":"Peng JC, Valouev A, Swigut T, Zhang J, Zhao Y, Sidow A, Wysocka J (2009) Jarid2\/Jumonji coordinates control of PRC2 enzymatic activity and target gene occupancy in pluripotent cells. Cell 139:1290\u20131302","journal-title":"Cell"},{"key":"1563_CR150","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/nature15520","volume":"527","author":"D Peng","year":"2015","unstructured":"Peng D, Kryczek I, Nagarsheth N, Zhao L, Wei S, Wang W, Sun Y, Zhao E, Vatan L, Szeliga W (2015) Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527:249\u2013253","journal-title":"Nature"},{"key":"1563_CR151","doi-asserted-by":"crossref","first-page":"5632","DOI":"10.1158\/1538-7445.AM2022-5632","volume":"82","author":"JET Perez","year":"2022","unstructured":"Perez JET, Dashwood RH (2022) Combinatorial epigenetic targeting of PRC2 complexes upregulates MHC antigen presentation components in melanoma and gastrointestinal cancer cells. Can Res 82:5632\u20135632","journal-title":"Can Res"},{"key":"1563_CR152","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.immuni.2016.10.032","volume":"45","author":"G Plitas","year":"2016","unstructured":"Plitas G, Konopacki C, Wu K, Bos PD, Morrow M, Putintseva EV, Chudakov DM, Rudensky AY (2016) Regulatory T cells exhibit distinct features in human breast cancer. Immunity 45:1122\u20131134","journal-title":"Immunity"},{"key":"1563_CR153","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41594-018-0023-y","volume":"25","author":"S Poepsel","year":"2018","unstructured":"Poepsel S, Kasinath V, Nogales E (2018) Cryo-EM structures of PRC2 simultaneously engaged with two functionally distinct nucleosomes. Nat Struct Mol Biol 25:154\u2013162","journal-title":"Nat Struct Mol Biol"},{"key":"1563_CR154","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004566","volume":"10","author":"R Popovic","year":"2014","unstructured":"Popovic R, Martinez-Garcia E, Giannopoulou EG, Zhang Q, Zhang Q, Ezponda T, Shah MY, Zheng Y, Will CM, Small EC (2014) Histone methyltransferase MMSET\/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation. PLoS Genet 10:e1004566","journal-title":"PLoS Genet"},{"key":"1563_CR155","doi-asserted-by":"publisher","unstructured":"Proudman DG, Gupta D, Nellesen D, Yang J, Kamp BA, Mamlouk K, Cheson BD (2022) Tazemetostat in relapsed\/refractory follicular lymphoma: a propensity score-matched analysis of E7438-G000\u2013101 trial outcomes. Oncotarget 13:677\u2013683. https:\/\/doi.org\/10.18632\/oncotarget.28229","DOI":"10.18632\/oncotarget.28229"},{"key":"1563_CR156","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ajh.22257","volume":"87","author":"A Puda","year":"2012","unstructured":"Puda A, Milosevic JD, Berg T, Klampfl T, Harutyunyan AS, Gisslinger B, Rumi E, Pietra D, Malcovati L, Elena C (2012) Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am J Hematol 87:245\u2013250","journal-title":"Am J Hematol"},{"key":"1563_CR157","doi-asserted-by":"crossref","first-page":"21360","DOI":"10.1073\/pnas.1210371110","volume":"109","author":"W Qi","year":"2012","unstructured":"Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, Zeng J, Li M, Fan H, Lin Y (2012) Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci 109:21360\u201321365","journal-title":"Proc Natl Acad Sci"},{"key":"1563_CR158","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1038\/s41375-018-0140-y","volume":"32","author":"N Rastgoo","year":"2018","unstructured":"Rastgoo N, Pourabdollah M, Abdi J, Reece D, Chang H (2018) Dysregulation of EZH2\/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS. Leukemia 32:2471\u20132482. https:\/\/doi.org\/10.1038\/s41375-018-0140-y","journal-title":"Leukemia"},{"key":"1563_CR159","doi-asserted-by":"publisher","first-page":"5721","DOI":"10.1007\/s11033-020-05619-9","volume":"47","author":"S Rezaei","year":"2020","unstructured":"Rezaei S, Hosseinpourfeizi MA, Moaddab Y, Safaralizadeh R (2020) Contribution of DNA methylation and EZH2 in SRBC down-regulation in gastric cancer. Mol Biol Rep 47:5721\u20135727. https:\/\/doi.org\/10.1007\/s11033-020-05619-9","journal-title":"Mol Biol Rep"},{"key":"1563_CR160","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.molcel.2014.06.005","volume":"55","author":"EM Riising","year":"2014","unstructured":"Riising EM, Comet I, Leblanc B, Wu X, Johansen JV, Helin K (2014) Gene silencing triggers polycomb repressive complex 2 recruitment to CpG islands genome wide. Mol Cell 55:347\u2013360","journal-title":"Mol Cell"},{"key":"1563_CR161","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1158\/1078-0432.CCR-16-2735","volume":"23","author":"O Rizq","year":"2017","unstructured":"Rizq O, Mimura N, Oshima M, Saraya A, Koide S, Kato Y, Aoyama K, Nakajima-Takagi Y, Wang C, Chiba T (2017) Dual inhibition of EZH2 and EZH1 sensitizes PRC2-dependent tumors to proteasome inhibition. Clin Cancer Res 23:4817\u20134830","journal-title":"Clin Cancer Res"},{"key":"1563_CR162","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1158\/1078-0432.Ccr-19-3741","volume":"26","author":"C Sarkozy","year":"2020","unstructured":"Sarkozy C, Morschhauser F, Dubois S, Molina T, Michot JM, Culli\u00e8res-Dartigues P, Suttle B, Karlin L, Le Gouill S, Picquenot JM, Dubois R, Tilly H, Herbaux C, Jardin F, Salles G, Ribrag V (2020) A LYSA phase Ib study of tazemetostat (EPZ-6438) plus R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with poor prognosis features. Clin Cancer Res 26:3145\u20133153. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-3741","journal-title":"Clin Cancer Res"},{"key":"1563_CR163","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0060113","volume":"6","author":"M Sauvageau","year":"2008","unstructured":"Sauvageau M, Sauvageau G (2008) Polycomb group genes: keeping stem cell activity in balance. PLoS Biol 6:e113","journal-title":"PLoS Biol"},{"key":"1563_CR164","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.3390\/cells10051056","volume":"10","author":"C Schiliro","year":"2021","unstructured":"Schiliro C, Firestein BL (2021) Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation. Cells 10:1056","journal-title":"Cells"},{"key":"1563_CR165","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/ng1950","volume":"39","author":"Y Schlesinger","year":"2007","unstructured":"Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, Eden E, Yakhini Z, Ben-Shushan E, Reubinoff BE (2007) Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39:232\u2013236","journal-title":"Nat Genet"},{"key":"1563_CR166","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","volume":"482","author":"J Schwartzentruber","year":"2012","unstructured":"Schwartzentruber J, Korshunov A, Liu X-Y, Jones DT, Pfaff E, Jacob K, Sturm D, Fontebasso AM, Quang D-AK, T\u00f6njes M (2012) Driver mutations in histone H3. 3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226\u2013231","journal-title":"Nature"},{"key":"1563_CR167","first-page":"1208","volume":"119","author":"J Score","year":"2012","unstructured":"Score J, Hidalgo-Curtis C, Jones AV, Winkelmann N, Skinner A, Ward D, Zoi K, Ernst T, Stegelmann F, D\u00f6hner K (2012) Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic\/myeloproliferative neoplasms. Blood J Am Soc Hematol 119:1208\u20131213","journal-title":"Blood J Am Soc Hematol"},{"key":"1563_CR168","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccell.2015.12.006","volume":"29","author":"M Serresi","year":"2016","unstructured":"Serresi M, Gargiulo G, Proost N, Siteur B, Cesaroni M, Koppens M, Xie H, Sutherland KD, Hulsman D, Citterio E (2016) Polycomb repressive complex 2 is a barrier to KRAS-driven inflammation and epithelial-mesenchymal transition in non-small-cell lung cancer. Cancer Cell 29:17\u201331","journal-title":"Cancer Cell"},{"key":"1563_CR169","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1084\/jem.20180801","volume":"215","author":"M Serresi","year":"2018","unstructured":"Serresi M, Siteur B, Hulsman D, Company C, Schmitt MJ, Lieftink C, Morris B, Cesaroni M, Proost N, Beijersbergen RL (2018) Ezh2 inhibition in Kras-driven lung cancer amplifies inflammation and associated vulnerabilities. J Exp Med 215:3115","journal-title":"J Exp Med"},{"key":"1563_CR170","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cell.2013.03.008","volume":"153","author":"H Shen","year":"2013","unstructured":"Shen H, Laird PW (2013) Interplay between the cancer genome and epigenome. Cell 153:38\u201355","journal-title":"Cell"},{"key":"1563_CR171","doi-asserted-by":"crossref","unstructured":"Shen X, Kim W, Fujiwara Y, Simon MD, Liu Y, Mysliwiec MR, Yuan G-C, Lee Y, Orkin SH (2009) Jumonji modulates polycomb activity and self-renewal versus differentiation of stem cells. Cell 139:1303\u20131314","DOI":"10.1016\/j.cell.2009.12.003"},{"key":"1563_CR172","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/onc.2012.110","volume":"32","author":"J Shi","year":"2013","unstructured":"Shi J, Wang E, Zuber J, Rappaport A, Taylor M, Johns C, Lowe SW, Vakoc CR (2013) The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9; NrasG12D acute myeloid leukemia. Oncogene 32:930\u2013938","journal-title":"Oncogene"},{"key":"1563_CR173","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/aps.2017.7","volume":"38","author":"Y Shi","year":"2017","unstructured":"Shi Y, Wang X-x, Zhuang Y-w, Jiang Y, Melcher K, Xu HE (2017) Structure of the PRC2 complex and application to drug discovery. Acta Pharmacol Sin 38:963\u2013976. https:\/\/doi.org\/10.1038\/aps.2017.7","journal-title":"Acta Pharmacol Sin"},{"key":"1563_CR174","doi-asserted-by":"crossref","unstructured":"Shin DS, Park K, Garon E, Dubinett S (2022) Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer. Semin Onco. WB Saunders, 49(3-4):306\u2013318","DOI":"10.1053\/j.seminoncol.2022.06.005"},{"key":"1563_CR175","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.1111\/cas.15555","volume":"113","author":"Y Shinno","year":"2022","unstructured":"Shinno Y, Takenobu H, Sugino RP, Endo Y, Okada R, Haruta M, Satoh S, Mukae K, Shaliman D, Wada T, Akter J, Ando K, Nakazawa A, Yoshida H, Ohira M, Hishiki T, Kamijo T (2022) Polycomb EZH1 regulates cell cycle\/5-fluorouracil sensitivity of neuroblastoma cells in concert with MYCN. Cancer Sci 113:4193\u20134206. https:\/\/doi.org\/10.1111\/cas.15555","journal-title":"Cancer Sci"},{"key":"1563_CR176","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.molcel.2013.02.013","volume":"49","author":"JA Simon","year":"2013","unstructured":"Simon JA, Kingston RE (2013) Occupying chromatin: polycomb mechanisms for getting to genomic targets, stopping transcriptional traffic, and staying put. Mol Cell 49:808\u2013824","journal-title":"Mol Cell"},{"key":"1563_CR177","doi-asserted-by":"crossref","first-page":"796","DOI":"10.3390\/cancers11060796","volume":"11","author":"R Singh","year":"2019","unstructured":"Singh R, Fazal Z, Corbet AK, Bikorimana E, Rodriguez JC, Khan EM, Shahid K, Freemantle SJ, Spinella MJ (2019) Epigenetic remodeling through downregulation of polycomb repressive complex 2 mediates chemotherapy resistance in testicular germ cell tumors. Cancers 11:796","journal-title":"Cancers"},{"key":"1563_CR178","doi-asserted-by":"crossref","first-page":"20980","DOI":"10.1073\/pnas.1012525107","volume":"107","author":"CJ Sneeringer","year":"2010","unstructured":"Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, Copeland RA (2010) Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci 107:20980\u201320985","journal-title":"Proc Natl Acad Sci"},{"key":"1563_CR179","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1101\/gad.225888.113","volume":"27","author":"J Son","year":"2013","unstructured":"Son J, Shen SS, Margueron R, Reinberg D (2013) Nucleosome-binding activities within JARID2 and EZH1 regulate the function of PRC2 on chromatin. Genes Dev 27:2663\u20132677","journal-title":"Genes Dev"},{"key":"1563_CR180","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.molcel.2016.05.004","volume":"62","author":"AA Soshnev","year":"2016","unstructured":"Soshnev AA, Josefowicz SZ, Allis CD (2016) Greater than the sum of parts: complexity of the dynamic epigenome. Mol Cell 62:681\u2013694","journal-title":"Mol Cell"},{"key":"1563_CR181","doi-asserted-by":"crossref","unstructured":"St. Jude Children's Research Hospital\u2013Washington University Pediatric Cancer Genome Project (2012) Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas.\u00a0Nat Genet\u00a044:251\u2013253","DOI":"10.1038\/ng.1102"},{"key":"1563_CR182","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.ccr.2012.08.024","volume":"22","author":"D Sturm","year":"2012","unstructured":"Sturm D, Witt H, Hovestadt V, Khuong-Quang D-A, Jones DT, Konermann C, Pfaff E, T\u00f6njes M, Sill M, Bender S (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425\u2013437","journal-title":"Cancer Cell"},{"key":"1563_CR183","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41388-018-0474-y","volume":"38","author":"A Swaroop","year":"2019","unstructured":"Swaroop A, Oyer JA, Will CM, Huang X, Yu W, Troche C, Bulic M, Durham BH, Wen QJ, Crispino JD (2019) An activating mutation of the NSD2 histone methyltransferase drives oncogenic reprogramming in acute lymphocytic leukemia. Oncogene 38:671\u2013686","journal-title":"Oncogene"},{"key":"1563_CR184","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/j.1349-7006.2011.01958.x","volume":"102","author":"M Takawa","year":"2011","unstructured":"Takawa M, Masuda K, Kunizaki M, Daigo Y, Takagi K, Iwai Y, Cho HS, Toyokawa G, Yamane Y, Maejima K (2011) Validation of the histone methyltransferase EZH2 as a therapeutic target for various types of human cancer and as a prognostic marker. Cancer Sci 102:1298\u20131305","journal-title":"Cancer Sci"},{"key":"1563_CR185","first-page":"1107","volume":"120","author":"S Tanaka","year":"2012","unstructured":"Tanaka S, Miyagi S, Sashida G, Chiba T, Yuan J, Mochizuki-Kashio M, Suzuki Y, Sugano S, Nakaseko C, Yokote K (2012) Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood J Am Soc Hematol 120:1107\u20131117","journal-title":"Blood J Am Soc Hematol"},{"key":"1563_CR186","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.3892\/or.2017.5430","volume":"37","author":"T Tao","year":"2017","unstructured":"Tao T, Chen M, Jiang R, Guan H, Huang Y, Su H, Hu Q, Han X, Xiao J (2017) Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b\/HK2 axis. Oncol Rep 37:1430\u20131436","journal-title":"Oncol Rep"},{"key":"1563_CR187","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1101\/gad.1464906","volume":"20","author":"AH Ting","year":"2006","unstructured":"Ting AH, McGarvey KM, Baylin SB (2006) The cancer epigenome\u2014components and functional correlates. Genes Dev 20:3215\u20133231","journal-title":"Genes Dev"},{"key":"1563_CR188","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.ccr.2013.04.020","volume":"23","author":"N Tiwari","year":"2013","unstructured":"Tiwari N, Tiwari VK, Waldmeier L, Balwierz PJ, Arnold P, Pachkov M, Meyer-Schaller N, Sch\u00fcbeler D, van Nimwegen E, Christofori G (2013) Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell 23:768\u2013783","journal-title":"Cancer Cell"},{"key":"1563_CR189","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.athoracsur.2018.08.056","volume":"107","author":"G Toyokawa","year":"2019","unstructured":"Toyokawa G, Takada K, Tagawa T, Hamamoto R, Yamada Y, Shimokawa M, Oda Y, Maehara Y (2019) A positive correlation between the EZH2 and PD-L1 expression in resected lung adenocarcinomas. Ann Thorac Surg 107:393\u2013400","journal-title":"Ann Thorac Surg"},{"key":"1563_CR190","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1126\/science.1192002","volume":"329","author":"M-C Tsai","year":"2010","unstructured":"Tsai M-C, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, Shi Y, Segal E, Chang HY (2010) Long noncoding RNA as modular scaffold of histone modification complexes. Science 329:689\u2013693","journal-title":"Science"},{"key":"1563_CR191","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.immuni.2013.09.012","volume":"39","author":"DJ Tumes","year":"2013","unstructured":"Tumes DJ, Onodera A, Suzuki A, Shinoda K, Endo Y, Iwamura C, Hosokawa H, Koseki H, Tokoyoda K, Suzuki Y (2013) The polycomb protein Ezh2 regulates differentiation and plasticity of CD4+ T helper type 1 and type 2 cells. Immunity 39:819\u2013832","journal-title":"Immunity"},{"issue":"549\u2013560","key":"1563_CR192","volume":"144","author":"D Tumes","year":"2019","unstructured":"Tumes D, Hirahara K, Papadopoulos M, Shinoda K, Onodera A, Kumagai J, Yip KH, Pant H, Kokubo K, Kiuchi M (2019) Ezh2 controls development of natural killer T cells, which cause spontaneous asthma-like pathology. J Allergy Clin Immunol 144(549\u2013560):e510","journal-title":"J Allergy Clin Immunol"},{"key":"1563_CR193","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1038\/leu.2012.146","volume":"26","author":"T Ueda","year":"2012","unstructured":"Ueda T, Sanada M, Matsui H, Yamasaki N, Honda Z, Shih L, Mori H, Inaba T, Ogawa S, Honda H (2012) EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms. Leukemia 26:2557\u20132560","journal-title":"Leukemia"},{"key":"1563_CR194","doi-asserted-by":"crossref","unstructured":"Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324:1029\u20131033","DOI":"10.1126\/science.1160809"},{"key":"1563_CR195","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1038\/nature01075","volume":"419","author":"S Varambally","year":"2002","unstructured":"Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, Ghosh D, Pienta KJ, Sewalt RG, Otte AP (2002) The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624\u2013629","journal-title":"Nature"},{"key":"1563_CR196","first-page":"5247","volume":"116","author":"I Velichutina","year":"2010","unstructured":"Velichutina I, Shaknovich R, Geng H, Johnson NA, Gascoyne RD, Melnick AM, Elemento O (2010) EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood J Am Soc Hematol 116:5247\u20135255","journal-title":"Blood J Am Soc Hematol"},{"key":"1563_CR197","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1038\/nature04431","volume":"439","author":"E Vir\u00e9","year":"2006","unstructured":"Vir\u00e9 E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden J-M (2006) The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439:871\u2013874","journal-title":"Nature"},{"key":"1563_CR198","doi-asserted-by":"publisher","unstructured":"Voigt P, LeRoy G, Drury William J III, Zee Barry M, Son J, Beck David B, Young Nicolas L, Garcia Benjamin A, Reinberg D (2012) Asymmetrically modified nucleosomes. Cell 151:181\u2013193. https:\/\/doi.org\/10.1016\/j.cell.2012.09.002","DOI":"10.1016\/j.cell.2012.09.002"},{"key":"1563_CR199","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.molcel.2017.12.024","volume":"69","author":"L Wan","year":"2018","unstructured":"Wan L, Xu K, Wei Y, Zhang J, Han T, Fry C, Zhang Z, Wang YV, Huang L, Yuan M, Xia W, Chang W-C, Huang W-C, Liu C-L, Chang Y-C, Liu J, Wu Y, Jin VX, Dai X, Guo J, Liu J, Jiang S, Li J, Asara JM, Brown M, Hung M-C, Wei W (2018) Phosphorylation of EZH2 by AMPK suppresses PRC2 methyltransferase activity and oncogenic function. Mol Cell 69:279-291.e275. https:\/\/doi.org\/10.1016\/j.molcel.2017.12.024","journal-title":"Mol Cell"},{"key":"1563_CR200","doi-asserted-by":"crossref","first-page":"27427","DOI":"10.18632\/oncotarget.4861","volume":"6","author":"J Wang","year":"2015","unstructured":"Wang J, Zhu X, Hu J, He G, Li X, Wu P, Ren X, Wang F, Liao W, Liang L (2015) The positive feedback between Snail and DAB2IP regulates EMT, invasion and metastasis in colorectal cancer. Oncotarget 6:27427","journal-title":"Oncotarget"},{"key":"1563_CR201","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1016\/j.celrep.2018.05.050","volume":"23","author":"D Wang","year":"2018","unstructured":"Wang D, Quiros J, Mahuron K, Pai C-C, Ranzani V, Young A, Silveria S, Harwin T, Abnousian A, Pagani M (2018) Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity. Cell Rep 23:3262\u20133274","journal-title":"Cell Rep"},{"key":"1563_CR202","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/nbt.3652","volume":"34","author":"A Weiner","year":"2016","unstructured":"Weiner A, Lara-Astiaso D, Krupalnik V, Gafni O, David E, Winter DR, Hanna JH, Amit I (2016) Co-ChIP enables genome-wide mapping of histone mark co-occurrence at single-molecule resolution. Nat Biotechnol 34:953\u2013961. https:\/\/doi.org\/10.1038\/nbt.3652","journal-title":"Nat Biotechnol"},{"key":"1563_CR203","doi-asserted-by":"crossref","first-page":"37974","DOI":"10.18632\/oncotarget.16467","volume":"8","author":"Y Wen","year":"2017","unstructured":"Wen Y, Cai J, Hou Y, Huang Z, Wang Z (2017) Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target. Oncotarget 8:37974","journal-title":"Oncotarget"},{"key":"1563_CR204","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/ng1941","volume":"39","author":"M Widschwendter","year":"2007","unstructured":"Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C, Weisenberger DJ, Campan M, Young J, Jacobs I (2007) Epigenetic stem cell signature in cancer. Nat Genet 39:157\u2013158","journal-title":"Nat Genet"},{"key":"1563_CR205","doi-asserted-by":"crossref","first-page":"3011","DOI":"10.1016\/j.febslet.2011.08.018","volume":"585","author":"TJ Wigle","year":"2011","unstructured":"Wigle TJ, Knutson SK, Jin L, Kuntz KW, Pollock RM, Richon VM, Copeland RA, Scott MP (2011) The Y641C mutation of EZH2 alters substrate specificity for histone H3 lysine 27 methylation states. FEBS Lett 585:3011\u20133014","journal-title":"FEBS Lett"},{"key":"1563_CR206","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ccr.2010.09.006","volume":"18","author":"BG Wilson","year":"2010","unstructured":"Wilson BG, Wang X, Shen X, McKenna ES, Lemieux ME, Cho Y-J, Koellhoffer EC, Pomeroy SL, Orkin SH, Roberts CW (2010) Epigenetic antagonism between polycomb and SWI\/SNF complexes during oncogenic transformation. Cancer Cell 18:316\u2013328","journal-title":"Cancer Cell"},{"key":"1563_CR207","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1007\/s13277-015-3195-7","volume":"36","author":"R Xia","year":"2015","unstructured":"Xia R, Jin F-y, Lu K, Wan L, Xie M, Xu T-p, De W, Wang Z-x (2015) SUZ12 promotes gastric cancer cell proliferation and metastasis by regulating KLF2 and E-cadherin. Tumor Biology 36:5341\u20135351","journal-title":"Tumor Biology"},{"key":"1563_CR208","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.exphem.2015.05.001","volume":"43","author":"B Xu","year":"2015","unstructured":"Xu B, Konze KD, Jin J, Wang GG (2015) Targeting EZH2 and PRC2 dependence as novel anticancer therapy. Exp Hematol 43:698\u2013712","journal-title":"Exp Hematol"},{"key":"1563_CR209","first-page":"1009","volume":"7","author":"CC Yang","year":"2015","unstructured":"Yang CC, LaBaff A, Wei Y, Nie L, Xia W, Huo L, Yamaguchi H, Hsu YH, Hsu JL, Liu D, Lang J, Du Y, Lien HC, Li LY, Deng R, Chan LC, Yao J, Kleer CG, Hortobagyi GN, Hung MC (2015) Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. Am J Transl Res 7:1009\u20131020","journal-title":"Am J Transl Res"},{"key":"1563_CR210","first-page":"2451","volume":"117","author":"DB Yap","year":"2011","unstructured":"Yap DB, Chu J, Berg T, Schapira M, Cheng S-WG, Moradian A, Morin RD, Mungall AJ, Meissner B, Boyle M (2011) Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood J Am Soc Hematol 117:2451\u20132459","journal-title":"Blood J Am Soc Hematol"},{"key":"1563_CR211","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1038\/s41598-017-03362-z","volume":"7","author":"X Yi","year":"2017","unstructured":"Yi X, Guo J, Guo J, Sun S, Yang P, Wang J, Li Y, Xie L, Cai J, Wang Z (2017) EZH2-mediated epigenetic silencing of TIMP2 promotes ovarian cancer migration and invasion. Sci Rep 7:3568","journal-title":"Sci Rep"},{"key":"1563_CR212","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.jid.2017.10.036","volume":"138","author":"S Yi","year":"2018","unstructured":"Yi S, Sun J, Qiu L, Fu W, Wang A, Liu X, Yang Y, Kadin ME, Tu P, Wang Y (2018) Dual role of EZH2 in cutaneous anaplastic large cell lymphoma: promoting tumor cell survival and regulating tumor microenvironment. J Investig Dermatol 138:1126\u20131136","journal-title":"J Investig Dermatol"},{"key":"1563_CR213","doi-asserted-by":"crossref","first-page":"8577","DOI":"10.1074\/jbc.RA118.006871","volume":"294","author":"NK Yiew","year":"2019","unstructured":"Yiew NK, Greenway C, Zarzour A, Ahmadieh S, Goo B, Kim D, Benson TW, Ogbi M, Tang YL, Chen W (2019) Enhancer of zeste homolog 2 (EZH2) regulates adipocyte lipid metabolism independent of adipogenic differentiation: role of apolipoprotein E. J Biol Chem 294:8577\u20138591","journal-title":"J Biol Chem"},{"key":"1563_CR214","doi-asserted-by":"crossref","first-page":"15988","DOI":"10.1073\/pnas.1521740112","volume":"112","author":"J Yin","year":"2015","unstructured":"Yin J, Leavenworth JW, Li Y, Luo Q, Xie H, Liu X, Huang S, Yan H, Fu Z, Zhang LY (2015) Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity. Proc Natl Acad Sci 112:15988\u201315993","journal-title":"Proc Natl Acad Sci"},{"key":"1563_CR215","volume":"7","author":"H Yu","year":"2012","unstructured":"Yu H, Simons DL, Segall I, Carcamo-Cavazos V, Schwartz EJ, Yan N, Zuckerman NS, Dirbas FM, Johnson DL, Holmes SP (2012) PRC2\/EED-EZH2 complex is up-regulated in breast cancer lymph node metastasis compared to primary tumor and correlates with tumor proliferation in situ. PLoS ONE 7:e51239","journal-title":"PLoS ONE"},{"key":"1563_CR216","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1182\/blood.V128.22.4495.4495","volume":"128","author":"T Yu","year":"2016","unstructured":"Yu T, Liu L, Zhang S, Hao M, Qiu L (2016) PHF19 promotes drug resistance through EZH2 inactivation in multiple myeloma. Blood 128:4495. https:\/\/doi.org\/10.1182\/blood.V128.22.4495.4495","journal-title":"Blood"},{"key":"1563_CR217","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/ni.3706","volume":"18","author":"B Yu","year":"2017","unstructured":"Yu B, Zhang K, Milner JJ, Toma C, Chen R, Scott-Browne JP, Pereira RM, Crotty S, Chang JT, Pipkin ME (2017) Epigenetic landscapes reveal transcription factors that regulate CD8+ T cell differentiation. Nat Immunol 18:573\u2013582","journal-title":"Nat Immunol"},{"key":"1563_CR218","doi-asserted-by":"crossref","first-page":"7983","DOI":"10.1074\/jbc.M110.194027","volume":"286","author":"W Yuan","year":"2011","unstructured":"Yuan W, Xu M, Huang C, Liu N, Chen S, Zhu B (2011) H3K36 methylation antagonizes PRC2-mediated H3K27 methylation. J Biol Chem 286:7983\u20137989","journal-title":"J Biol Chem"},{"key":"1563_CR219","doi-asserted-by":"publisher","first-page":"911","DOI":"10.7150\/ijbs.64752","volume":"18","author":"S Yuan","year":"2022","unstructured":"Yuan S, Xu J, Zhou B, Zhou Y, Lang M, Cao J, Liu Z, Yang S, Gao S, Hao J (2022) SOX8 Affects Tumoral SPARC Expression by Regulating EZH2 to Attenuate Effectiveness of albumin-bound paclitaxel in PDAC. Int J Biol Sci 18:911\u2013922. https:\/\/doi.org\/10.7150\/ijbs.64752","journal-title":"Int J Biol Sci"},{"key":"1563_CR220","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/nature10725","volume":"481","author":"J Zhang","year":"2012","unstructured":"Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, Payne-Turner D, Easton J, Chen X, Wang J, Rusch M (2012) The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481:157\u2013163","journal-title":"Nature"},{"key":"1563_CR221","first-page":"1","volume":"12","author":"T Zhang","year":"2020","unstructured":"Zhang T, Gong Y, Meng H, Li C, Xue L (2020) Symphony of epigenetic and metabolic regulation\u2014interaction between the histone methyltransferase EZH2 and metabolism of tumor. Clin Epigenetics 12:1\u201315","journal-title":"Clin Epigenetics"},{"key":"1563_CR222","doi-asserted-by":"crossref","unstructured":"Zhang T, Guo Z, Huo X, Gong Y, Li C, Huang J, Wang Y, Feng H, Ma X, Jiang C (2022) Dysregulated lipid metabolism blunts the sensitivity of cancer cells to EZH2 inhibitor. EBioMedicine 77","DOI":"10.1016\/j.ebiom.2022.103872"},{"key":"1563_CR223","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bbrc.2019.07.039","volume":"517","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Wang X-X, Wu W, Long H, Huang J, Wang Z, Li T, Tang S, Zhu B, Chen D (2019) EZH2 regulates PD-L1 expression via HIF-1\u03b1 in non-small cell lung cancer cells. Biochem Biophys Res Commun 517:201\u2013209","journal-title":"Biochem Biophys Res Commun"},{"key":"1563_CR224","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114144","volume":"231","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Guan Y-Y, Zhao F, Yu T, Zhang S-J, Zhang Y-Z, Duan Y-C, Zhou X-L (2022) Recent strategies targeting embryonic ectoderm development (EED) for cancer therapy: allosteric inhibitors, PPI inhibitors, and PROTACs. Eur J Med Chem 231:114144","journal-title":"Eur J Med Chem"},{"key":"1563_CR225","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2023.109389","volume":"227","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Cheng Y, Qu Y (2023) The role of EZH2 as a potential therapeutic target in retinoblastoma. Exp Eye Res 227:109389. https:\/\/doi.org\/10.1016\/j.exer.2023.109389","journal-title":"Exp Eye Res"},{"key":"1563_CR226","doi-asserted-by":"crossref","first-page":"13549","DOI":"10.1073\/pnas.1205707109","volume":"109","author":"Y Zheng","year":"2012","unstructured":"Zheng Y, Sweet SM, Popovic R, Martinez-Garcia E, Tipton JD, Thomas PM, Licht JD, Kelleher NL (2012) Total kinetic analysis reveals how combinatorial methylation patterns are established on lysines 27 and 36 of histone H3. Proc Natl Acad Sci 109:13549\u201313554","journal-title":"Proc Natl Acad Sci"},{"key":"1563_CR227","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1158\/1078-0432.Ccr-19-1351","volume":"26","author":"L Zhou","year":"2020","unstructured":"Zhou L, Mudianto T, Ma X, Riley R, Uppaluri R (2020) Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti\u2013PD-1 resistance in head and neck cancer. Clin Cancer Res 26:290\u2013300. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-1351","journal-title":"Clin Cancer Res"},{"key":"1563_CR228","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150026","volume":"11","author":"Z Zhu","year":"2016","unstructured":"Zhu Z, Tang J, Wang J, Duan G, Zhou L, Zhou X (2016) MiR-138 acts as a tumor suppressor by targeting EZH2 and enhances cisplatin-induced apoptosis in osteosarcoma cells. PLoS ONE 11:e0150026. https:\/\/doi.org\/10.1371\/journal.pone.0150026","journal-title":"PLoS ONE"},{"key":"1563_CR229","first-page":"3267","volume":"10","author":"J Zhu","year":"2020","unstructured":"Zhu J, Li L, Tong J, Hui C, Wong CH, Lo KW, Chan R, Ai QY, Hui EP, Chan ATC (2020) Targeting the polycomb repressive complex-2 related proteins with novel combinational strategies for nasopharyngeal carcinoma. Am J Cancer Res 10:3267","journal-title":"Am J Cancer Res"},{"key":"1563_CR230","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.celrep.2017.07.007","volume":"20","author":"D Zingg","year":"2017","unstructured":"Zingg D, Arenas-Ramirez N, Sahin D, Rosalia RA, Antunes AT, Haeusel J, Sommer L, Boyman O (2017) The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy. Cell Rep 20:854\u2013867","journal-title":"Cell Rep"}],"container-title":["Functional & Integrative Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-025-01563-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10142-025-01563-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10142-025-01563-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T08:12:21Z","timestamp":1769155941000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10142-025-01563-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":230,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1563"],"URL":"https:\/\/doi.org\/10.1007\/s10142-025-01563-8","relation":{},"ISSN":["1438-793X","1438-7948"],"issn-type":[{"value":"1438-793X","type":"print"},{"value":"1438-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"29 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}